Metabolic Syndrome Increases the Risk of Kidney Stone Disease: A Cross-Sectional and Longitudinal Cohort Study

Che-Wei Chang 1,2, Hung-Lung Ke 2,3,4,5, Jia-In Lee 6, Yung-Chin Lee 1,2, Jhen-Hao Jhan 1,2, Hsuen-Shuan Wang 1,2, Jung-Tsung Shen 1, Yao-Hsuan Tsao 1,2, Shu-Pin Huang 2,3,4,5 and Jiun-Hung Geng 1,2,3,4,5,7,*

Abstract: We aimed to examine the association between metabolic syndrome and the risk of kidney stone development in a large-scale community-based cohort. A total of 121,579 participants enrolled in the Taiwan Biobank were analyzed. They were divided into two groups on the basis of presence of metabolic syndrome. The presence of kidney stone disease was defined by self-reported history of kidney stones. The mean age of participants was 50 years old, and self-reported kidney stones were observed in 3446 (10%) and 4292 (5%) participants with metabolic syndrome and without metabolic syndrome, respectively. Higher prevalence of kidney stone disease was found in participants with metabolic syndrome compared to those without metabolic syndrome (odds ratio (OR), 1.32; 95% confidence interval (95% CI), 1.25 to 1.39). In addition, the risk of incident kidney stone development was analyzed in a longitudinal cohort of 25,263 participants without kidney stones at baseline during a mean follow-up of 47 months. Multivariable Cox regression analysis revealed that the risk for incident kidney stone disease was higher in participants with metabolic syndrome than those without metabolic syndrome (hazard ratio, 1.24; 95% CI, 1.04 to 1.49). Our study suggests that metabolic syndrome does increase the risk of kidney stones.

Keywords: epidemiologic study; longitudinal study; kidney stone; metabolic syndrome; risk factors; diabetes mellitus; hypertension; dyslipidemia

1. Introduction

Kidney stone disease (KSD) is a global health problem with an increasing cumulative incidence in the U.S. and other countries [1]. The overall lifetime risk of KSD in Taiwan is around 10% [2], which is similar to global trends [3]. Kidney stones could lead to ureteral obstruction, resulting in life-threatening conditions such as septic shock. It could also result in chronic kidney diseases [4]. The pathophysiology of stone formation is a multifactorial combination of genetics, dietary, metabolic, and environmental components [5]. Many associated risk factors have been reported in the past few decades. Obesity, diabetes mellitus (DM) and hypertension are linked to increased risk of stone formation. Therefore,
it is crucial for us to identify modifiable factors in order to prevent or decrease the risk of renal stone disease.

Metabolic syndrome comprises of hypertension, obesity, hyperlipidemia, and hyperglycemia. The correlation between metabolic syndrome and renal stones has been reported in several cross-sectional studies [6,7]. However, only few longitudinal cohort studies have been reported [8]. We aimed to examine the association between metabolic syndrome and the risk of kidney stone development in a large-scale community-based cohort in Taiwan.

2. Materials and Methods

2.1. Data Source and Study Population

The data acquisition was from Taiwan Biobank (TWB), a large-scale community-based research database comprised of cancer-free volunteers aged between 30 and 70 years. It enrolled through 29 recruitment centers in Taiwan since 2008. The detailed profile and methods concerning the development of TWB has been described in previous studies [9]. A total of 121,579 participants with adequate baseline were enrolled in the cross-sectional study, as shown in Supplementary Figure S1.

In the longitudinal cohort, participants with known underlying KSD (N = 1946) were excluded. A total of 25,263 participants were examined in the final analysis (Supplementary Figure S1). Participants underwent serial physical examination, biospecimen collection, and questionnaire surveys every 2 to 4 years from 2008 to 2019. Written informed consent was obtained from all participants and all investigations were conducted according to the Declaration of Helsinki. This study was approved by the Institutional Review Board of Kaohsiung Medical University Hospital (KMUHIRB-E(I)-20190398).

2.2. Metabolic Syndrome Definition and Assessments

Metabolic syndrome was diagnosed if three or more of the following five traits are present, according to the definition proposed by the Bureau of Health Promotion (Taiwan) in 2006 [10]: central obesity defined as waist circumference ≥90 cm (men) or ≥80 cm (women), blood pressure ≥130/85 mmHg, serum fasting triglyceride level ≥150 mg/dL, serum fasting high-density lipoprotein (HDL) cholesterol level <40 mg/dL (men) or <50 mg/dL (women), and fasting blood sugar ≥100 mg/dL. The related physical examinations and blood tests were completed in all subjects.

2.3. Self-Reported KSD

In standardized interviews, participants were asked “Have you ever had KSD?”, “What was the time of diagnosis.” The same questions were repeated during every 2 to 4 years follow-up interviews.

2.4. Study Outcome

In the cross-sectional cohort, the association between metabolic syndrome and the prevalence of KSD was evaluated. As for the longitudinal cohort, the primary end point was the development of KSD. As stated above, we had excluded participants with a history of KSD. All subjects in this study had no history of kidney stone at baseline. The association between metabolic syndrome and subsequent KSD was further assessed.

2.5. Statistical Analyses

Participants in the present study were stratified into a metabolic syndrome group and a non-metabolic syndrome group. Clinical characteristics were presented as percentages for categorical variables and mean ± standard deviation for continuous variables. The statistical significance of differences among categorical variables was assessed using the Pearson χ² test and among continuous variables was assessed using an independent t-test. In the cross-sectional cohort, logistic regression was used to analyze the association between metabolic syndrome and the prevalence of KSD before and after adjusting for potential epidemiologic variables (age, sex, smoke status, alcohol status, marital status,
and educational status), and laboratory factors (estimated glomerular filtration rate, serum hemoglobin, serum albumin, and serum uric acid). In the longitudinal cohort, the cumulative event-free survival rates were estimated with Kaplan–Meier analysis and a log-rank test. Event-free survival time was defined as the interval between baseline and primary end point or the last date of follow-up. Participants who died or were lost to follow-up were censored at the date of the last examination. All analyses were carried out using SPSS 20.0 (IBM Corp, Armonk, NY, USA) and R version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria) and a p value of < 0.05 was considered statistically significant.

3. Results
3.1. Clinical Profiles of the Study Participants

Of the 121,579 included participants, mean ages were 54 ± 10 and 49 ± 11 years in the metabolic syndrome and the non-metabolic syndrome group, respectively. The majority of the subjects (64%) were female and 23% (N = 27,425) had metabolic syndrome (Table 1). The greatest frequency of metabolic syndrome trait regardless of the number of traits presented was increased waist circumference. The second greatest frequency metabolic syndrome trait was hypertension (Table 1). Adults with metabolic syndromes tended to be older with higher blood pressure, serum total cholesterol, triglycerides, blood sugar, uric acid, low density lipoproteins, and have larger waist circumference than those in the non-metabolic syndrome group (Table 1).

| Characteristics | Total (N = 121,579) | Metabolic Syndrome (N = 27,425) | No Metabolic Syndrome (N = 94,154) | P Value |
|-----------------|---------------------|---------------------------------|-----------------------------------|---------|
| Demographic data |                     |                                 |                                   |         |
| Age, y          | 50 ± 11             | 54 ± 10                         | 49 ± 11                           | <0.001  |
| Women, n (%)    | 77,884 (64)         | 15,443 (56)                     | 62,441 (66)                       | <0.001  |
| BMI, kg/m²      | 24.2 ± 3.8          | 27.3 ± 3.8                      | 23.3 ± 3.3                        | <0.001  |
| Smoke, ever, n (%) | 33,151 (27)     | 9288 (34)                       | 23,863 (25)                       | <0.001  |
| Alcohol status, ever, n (%) | 10,357 (9) | 3294 (12)                      | 7063 (8)                          | <0.001  |
| Physical activity, yes, n (%) | 49,296 (41) | 11,181 (41)                    | 38,115 (41)                       | 0.394   |
| Married, yes, n (%) | 105,040 (86)     | 24,732 (90)                     | 80,308 (85)                       | <0.001  |
| Education status, n (%) |                     |                                 |                                   | <0.001  |
| ≤Elementary     | 6418 (Elementary)   | 2472 (9)                        | 3946 (4)                          |         |
| Middle to High school | 44,690 (37) | 11,759 (43)                    | 32,931 (35)                       |         |
| ≥College         | 70,471 (58)         | 13,194 (48)                     | 57,277 (61)                       |         |
| Systolic BP, mm Hg | 120 ± 19            | 133 ± 18                        | 91 ± 17                           | <0.001  |
| Diastolic BP, mm Hg | 74 ± 11             | 81 ± 11                         | 68 ± 11                           | <0.001  |
| Individual components of metabolic syndrome |                     |                                 |                                   |         |
| Hypertension *, n (%) | 42,756 (35)     | 20,537 (75)                     | 22,219 (24)                       | <0.001  |
| Impaired glucose tolerance †, n (%) | 25,291 (21) | 15,449 (56)                    | 9842 (11)                         | <0.001  |
| Increased waist circumference ‡, n (%) | 56,467 (46) | 24,037 (88)                    | 32,430 (34)                       | <0.001  |
| Hypertriglyceridemia §, n (%) | 25,440 (21) | 17,536 (64)                    | 790 (8)                           | <0.001  |
| Low high-density lipoprotein cholesterol ․, n (%) | 90,490 (74) | 70,471 (58)                    | 13,155 (14)                       | <0.001  |
| Laboratory data |                     |                                 |                                   |         |
| eGFR, ml/min per 1.73 m² | 103 ± 24            | 98 ± 24                         | 105 ± 24                           | <0.001  |
| Hemoglobin, g/dL | 13.8 ± 1.6          | 14.2 ± 1.6                      | 13.6 ± 1.6                        | <0.001  |
| Albumin, g/dL    | 4.5 ± 0.2           | 4.5 ± 0.2                       | 4.5 ± 0.2                         | <0.001  |
| Fasting glucose, mg/dL | 96 ± 21            | 109 ± 33                        | 29 ± 13                           | <0.001  |
| Hemoglobin A1c, % | 5.8 ± 0.8           | 6.3 ± 1.2                       | 5.6 ± 0.6                         | <0.001  |
| Total cholesterol, mg/dL | 196 ± 36         | 200 ± 39                        | 195 ± 35                          | 0.134   |
| Triglyceride, mg/dL | 116 ± 94            | 195 ± 164                       | 93 ± 53                           | <0.001  |
| HDL cholesterol, mg/dL | 55 ± 13             | 44 ± 9                         | 58 ± 13                           | <0.001  |
| LDL cholesterol, mg/dL | 121 ± 32            | 124 ± 34                        | 120 ± 31                          | 0.004   |
| Uric acid, mg/dL | 5.4 ± 1.4           | 6.1 ± 1.5                       | 5.2 ± 1.3                         | <0.001  |

BMI = body mass index; BP = blood pressure; eGFR = estimated glomerular filtration rate; IQR = interquartile range; HDL = high-density lipoproteins; LDL = low-density lipoproteins. * Systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥85 mm Hg. † Fasting glucose level ≥100 mg/dL. ‡ Waist circumference ≥90 cm for men and ≥80 cm for women. § Serum triglyceride level ≥150 mg/dL. ¶ High-density lipoprotein cholesterol level <40 mg/dL for men and <50 mg/dL for women.
3.2. Metabolic Syndrome Was Associated with an Increasing Risk of KSD

In univariate binary regression analysis without adjustment, the presence of metabolic syndrome was associated with a 1.79-fold increase of KSD (odds ratio (OR), 1.79; 95% confidence interval (95% CI), 1.70 to 1.88) (Table 2). After adjustment for potential epidemiologic variables, including age, sex, smoke status (never vs. ever), alcohol status (never vs. ever), marital status (yes vs. no), and educational status, the odds decreased to 1.42 (OR, 1.42; 95% CI, 1.35 to 1.49) (Table 2). Similar results were found when adjusted for potentially relevant laboratory factors (estimated glomerular filtration rate, serum hemoglobin, serum albumin, and serum uric acid) (OR, 1.32; 95% CI, 1.25 to 1.39) (Table 2). Furthermore, the presence of more than three metabolic syndrome traits did increase the OR of KSD in a traits-dependent fashion. The OR increased to 2.02 in the subjects with five metabolic syndrome traits (OR, 2.02; 95% CI, 1.76 to 2.33) (Table 2).

Table 2. Odds ratios for self-reported kidney stone disease (n = 121,579).

| Variables | No. of KSD Cases/No. of Subjects (%) | Unadjusted Odds Ratio (95% CI) | Model 1 Odds Ratio (95% CI) | Model 2 Odds Ratio (95% CI) |
|-----------|-------------------------------------|------------------------------|-----------------------------|-----------------------------|
| Metabolic syndrome (yes vs. no) | | | | |
| No | 4292/94,154 (5) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
| Yes | 3446/27,425 (10) | 1.79 (1.70 to 1.88) | 1.42 (1.35 to 1.49) | 1.32 (1.25 to 1.39) |
| No. of metabolic syndrome traits | | | | |
| 0 | 1305/34,614 (4) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
| 1 | 1902/33,530 (6) | 1.54 (1.43 to 1.65) | 1.27 (1.18 to 1.37) | 1.24 (1.15 to 1.33) |
| 2 | 1955/26,010 (8) | 2.07 (1.93 to 2.23) | 1.54 (1.43 to 1.66) | 1.45 (1.35 to 1.57) |
| 3 | 1438/16,725 (9) | 2.40 (2.22 to 2.59) | 1.67 (1.54 to 1.80) | 1.54 (1.42 to 1.67) |
| 4 | 847/8182 (10) | 2.95 (2.69 to 3.23) | 1.99 (1.82 to 2.19) | 1.81 (1.64 to 1.99) |
| 5 | 291/2518 (12) | 3.34 (2.92 to 3.81) | 2.25 (1.96 to 2.58) | 2.02 (1.76 to 2.33) |

CI = confidence interval; KSD = kidney stone disease. Model 1 adjusts for potential epidemiologic variables, including age, sex, smoke status, alcohol status, marital status, and educational status. Model 2 adds laboratory factors, including estimated glomerular filtration rate, serum hemoglobin, serum albumin, and serum uric acid to Model 1.

3.3. The Association between Individual Components of Metabolic Syndrome and KSD

Using the sub-distribution regression model, statistically significant associations of prevalence of KSD and all individual metabolic conditions were observed (Table 3). Among the five individual components of metabolic syndrome, most increased odds of KSD were observed in patients with hypertension (OR, 1.30; 95% CI, 1.24 to 1.37) (Table 3).

3.4. Association of Metabolic Syndrome with Incident KSD Development

In the longitudinal cohort, a total of 25,263 participants with no prior KSD were included in the analysis with a mean age of 51 years and 66% were female. Of all participants, 23% had smoking experience and 21% had metabolic syndrome (Supplementary Table S1). A total of 642 participants (3% of the study population) had development of KSD during a mean follow-up duration of 47 months. Multivariable Cox regression analysis revealed that the risk for incident KSD was higher in participants with metabolic syndrome than those without metabolic syndrome (hazard ratio (HR), 1.24; 95% CI, 1.04 to 1.49) (Table 4). Furthermore, subjects with five traits of metabolic syndrome showed the highest risk of developing KSD (HR, 1.54; 95% CI, 0.91 to 2.62) (Table 4). The Kaplan–Meier plot of incident KSD development according to the presence of metabolic syndrome was shown in Figure 1. The time to KSD development was longer in participants without metabolic syndrome than participants with metabolic syndrome (p value = 0.019).
Two longitudinal studies also found an increased risk of subsequent KSD in hypertensive patients [12,13]. Hypertension is a major risk factor for cardiovascular diseases, and a metabolic syndrome, most increased odds of KSD were observed in patients with the development of KSD during a period of time.

However, it lacked data on women and did not adjust for potential risk factors, such as smoking, alcohol consumption, and marital status. In this cross-sectional and longitudinal study of a nationwide population in Taiwan, the information of gender, smoking, drinking, and laboratory factors, which allowed us to examine the cause and effect relationship between metabolic syndrome and the development of KSD.

Table 3. Odds ratios for self-reported kidney stone disease by individual components of metabolic syndrome (n = 121,579).

| Individual Component of Metabolic Syndrome | Unadjusted Odds Ratio (95% CI) | Model 1 Odds Ratio (95% CI) | Model 2 Odds Ratio (95% CI) | Model 3 Odds Ratio (95% CI) |
|------------------------------------------|-------------------------------|-----------------------------|-----------------------------|-----------------------------|
| Hypertension *                           | 2.15 (2.06 to 2.26)          | 1.44 (1.37 to 1.51)         | 1.37 (1.30 to 1.44)         | 1.30 (1.24 to 1.37)         |
| Impaired glucose tolerance †            | 1.79 (1.70 to 1.88)          | 1.24 (1.17 to 1.30)         | 1.19 (1.13 to 1.26)         | 1.11 (1.06 to 1.18)         |
| Increased waist circumference ‡         | 1.27 (1.21 to 1.33)          | 1.34 (1.28 to 1.41)         | 1.26 (1.20 to 1.32)         | 1.16 (1.10 to 1.22)         |
| Hypertriglyceridemia §                   | 1.65 (1.57 to 1.74)          | 1.32 (1.25 to 1.39)         | 1.22 (1.15 to 1.28)         | 1.12 (1.05 to 1.18)         |
| Low high-density lipoprotein ||| | 1.15 (1.09 to 1.21) | 1.22 (1.16 to 1.28) | 1.16 (1.10 to 1.23) | 1.06 (1.00 to 1.12) |

CI = confidence interval. * Systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 85 mm Hg. † Fasting glucose level ≥ 100 mg/dL. ‡ Waist circumference ≥ 90 cm for men and ≥ 80 cm for women. § Serum triglyceride level ≥ 150 mg/dL. || High-density lipoprotein cholesterol level < 40 mg/dL for men and < 50 mg/dL for women. Model 1 adjusts for potential epidemiologic variables, including age, sex, smoking status, alcohol status, marital status, and educational status. Model 2 adds laboratory factors, including estimated glomerular filtration rate, serum hemoglobin, serum albumin, and serum uric acid to Model 1. Model 3 adds individual components to Model 2.

Table 4. Relative risk for incident kidney stone according to the presence of metabolic syndrome.

| Variables                          | No. of incidental KSD Cases/No. of Subjects (%) | Adjusted Hazard Ratio (95% CI) | p Value |
|------------------------------------|-----------------------------------------------|--------------------------------|---------|
| Metabolic syndrome (yes vs. no)    |                                               |                                |         |
| No                                 | 460/19,948 (2.3)                               | 1.00 (Reference)               |         |
| Yes                                | 182/5315 (3.4)                                 | 1.24 (1.04 to 1.49)            | 0.019   |
| No. of metabolic syndrome traits   |                                               |                                |         |
| 0                                  | 140/7115 (2)                                   | 1.00 (Reference)               |         |
| 1                                  | 146/7038 (2)                                   | 0.94 (0.74 to 1.19)            | 0.610   |
| 2                                  | 174/5335 (3)                                   | 1.40 (1.11 to 1.77)            | 0.005   |
| 3                                  | 119/3225 (4)                                   | 1.42 (1.09 to 1.84)            | 0.008   |
| 4                                  | 47/1516 (3)                                    | 1.30 (0.92 to 1.84)            | 0.140   |
| 5                                  | 16/392 (4)                                     | 1.54 (0.91 to 2.62)            | 0.111   |

CI = confidence interval; KSD = kidney stone disease. Multivariable model: adjustment for age, sex, smoking status, alcohol status, marital status, educational status, estimated glomerular filtration rate, serum hemoglobin, serum albumin, and serum uric acid.

Figure 1. Time to kidney stone disease development was longer in participants without metabolic syndrome than participants with metabolic syndrome. Kaplan–Meier plot of incident kidney stone disease development according to the presence of metabolic syndrome in 25,263 participants with follow-up data.
4. Discussion

In this cross-sectional and longitudinal study of a nationwide population in Taiwan, metabolic syndrome is significantly associated with an increased risk of subsequent KSD after adjustment for covariates. We also noted that the presence of five traits was associated with a more than two-fold increase in odds of KSD, and all components of the metabolic syndrome were associated with a higher prevalence of KSD. To the best of our knowledge, this is the largest longitudinal study on the development of KSD in those with metabolic syndrome, and our results confirmed previous observations that participants with more individual metabolic conditions (hypertension, obesity, DM, and dyslipidemia) had a significantly increased risk of KSD.

Previously, a study of 3872 Korean men without KSD at baseline observed an increased risk of KSD in the metabolic syndrome group compared to the non-metabolic group (HR, 1.771, 95% CI, 1.157 to 2.711) during a mean follow-up duration of 5.77 years [8]. However, it lacked data on women and did not adjust for potential risk factors, such as smoking and drinking. In the present study, we enrolled more than 100,000 participants, and over 20,000 of them had sufficient follow-up. In addition, we collected the information of gender, smoking, drinking, and laboratory factors, which allowed us to adjust for the potential cofounders. The large sample size and detailed information allowed us to examine the cause and effect relationship between metabolic syndrome and the development of KSD during a period of time.

Interestingly, our study showed that among the five individual components of metabolic syndrome, most increased odds of KSD were observed in patients with hypertension. Hypertension is a major risk factor for cardiovascular diseases, and a correlation between KSD and hypertension has been suggested [11]. Two longitudinal studies also found an increased risk of subsequent KSD in hypertensive patients [12,13]. Furthermore, familial hypertensive patients tend to have hypercalciuria and hyperuricosuria, which results in KSD [14].

In line with previous studies, we also found that the presence of increased waist circumference, impaired glucose tolerance, hypertriglyceridemia, and low HDL were associated with an increased risk of KSD [15–20]. It is worth noting that our research used waist circumference to represent obesity as opposed to BMI, which could provide an insight into the impact of adiposopathy on KSD. Furthermore, impaired glucose tolerance was used to explore the effects of prediabetes on KSD. These findings could help us with early detection and early control of these diseases to prevent the further development of KSD.

A strength of our study is that we demonstrated a dose-response effect between the traits of metabolic syndrome and the risk of KSD. The odds of KSD were 1.54, 1.81 and 2.02 among subjects with 3, 4, and 5 traits of metabolic syndrome. Similar results were noted in a large Japanese cohort [21]. However, the definitions of metabolic syndrome and individual components in this study did not use ATP III definition. Blood pressure ≥140/90 mm Hg, BMI ≥ 25 kg/m², and fasting plasma glucose level ≥126 mg/dL were used, which could not represent the early status of metabolic syndrome. Furthermore, our study population is bigger than theirs and provides greater power to perform the subgroup analysis.

Several mechanisms have been proposed to explain the association between metabolic syndrome and the development of KSD, including hyperglycemia [19], insulin resistance [22], and vascular dysfunction [23]. Studies have shown that hyperglycemia can increase the secretion of urinary calcium, uric acid, phosphorus, and oxalate, and insulin resistance can lead to a decrease in urine ammonium and PH value, both of which contribute to stone formation [19,22]. Another mechanism proposed to mediate the association between KSD and metabolic syndrome has been vascular dysfunction, which is closely tied to metabolic syndrome. Two studies demonstrated that vascular dysfunction could cause the formation of Randall’s plaques, and initiated the formation of kidney stones [23,24].

The implication of this study is that the incidence of KSD could be reduced by modifying each component in metabolic syndrome. Studies on the Dietary Approaches to Stop Hypertension (DASH) have found that the DASH-style diet could decrease blood pressure,
lower oxidative stress induced by acute hyperlipidemia, and reduce the risk of KSD [25,26]. In addition, lifestyle modification, such as diet habit and weight loss could also reduce the risk of KSD as well as other cardiovascular diseases [26].

Our study demonstrated a strong association between metabolic syndrome and KSD. It is also currently the largest longitudinal community-based cohort, with detailed information and regular follow-up. Despite these strengths, there are some limitations in the current study. First of all, self-reported kidney stones were obtained by questionnaires without radiographic verification. Nevertheless, this substitution had been verified in several studies [6,21]. Moreover, Wu et al., reported a moderate concordance between claims records and self-reported renal diseases in Taiwan [27]. Second, we lacked information on diet and daily fluid amount because these factors can easily fluctuate and are difficult to record in detail. Third, we lacked specific information on stone types, but the majority of kidney stones in Taiwan are calcium oxalate, followed by calcium phosphate, and uric acid stones. Magnesium ammonium phosphate stones are rare [28]. Fourth, this study did not include subgroups of children or pregnant women, because this cohort study only included adults and no information about pregnancy status. Fifth, we lacked information regarding performance status, and subjects with poor performance status have a higher risk of developing infection stones [29]. Nevertheless, most participants were 30 to 70 years old, healthy, and cancer-free. Performance status was either 0 or 1.

5. Conclusions

Our study demonstrates that metabolic syndrome strongly increases the risk of developing kidney stones as the number of individual traits increases. High blood pressure is the most significant independent component in stone formation. This implies that weight loss, dietary habits, and blood pressure control may reduce the risk of kidney stone development.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/jpm11111154/s1, Figure S1: Study participants were classified by the presence of metabolic syndrome, Table S1: Clinical characteristics of the longitudinal cohort of participants.

Author Contributions: Conceptualization, C.-W.C., H.-L.K., Y.-C.L., J.-H.J., H.-S.W., J.-T.S., Y.-H.T., S.-P.H. and J.-H.G.; methodology, C.-W.C., J.-I.L. and J.-H.G.; software, J.-I.L. and J.-H.G.; validation, J.-H.G.; formal analysis, J.-I.L. and J.-H.G.; investigation, J.-H.G.; resources, S.-P.H. and J.-H.G.; data curation, C.-W.C., H.-L.K., S.-P.H. and J.-H.G.; writing—original draft preparation, C.-W.C., H.-L.K. and J.-H.G.; writing—review and editing, C.-W.C. and J.-H.G.; visualization, C.-W.C. and J.-H.G.; supervision, J.-H.G.; project administration, J.-H.G.; funding acquisition, none. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Kaohsiung Medical University Hospital (KMU-HIRB-E(I)-20190398).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper.

Data Availability Statement: Restrictions apply to the availability of these data. Data were obtained from Taiwan Biobank and are available with the permission of Taiwan Biobank.

Acknowledgments: This work was supported partially by the Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan, by Kaohsiung Medical University Research Center Grant (KMU-TCI09A01-1) and by Kaohsiung Municipal Siaogang Hospital (S-108-017).

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Raheem, O.A.; Khandvala, Y.S.; Sur, R.L.; Ghani, K.R.; Denstedt, J.D. Burden of Urolithiasis: Trends in Prevalence, Treatments, and Costs. *Eur. Urol. Focus* 2017, 3, 18–26. [CrossRef]

2. Huang, W.Y.; Chen, Y.F.; Carter, S.; Chang, H.C.; Lan, C.F.; Huang, K.H. Epidemiology of upper urinary tract stone disease in a Taiwanese population: A nationwide, population based study. *J. Urol.* 2013, 189, 2158–2163. [CrossRef]

3. Romero, V.; Akpinar, H.; Assimos, D.G. Kidney stones: A global picture of prevalence, incidence, and associated risk factors. *Rev. Urol.* 2010, 12, e86–e96.

4. Rule, A.D.; Bergstralh, E.J.; Melton, L.J.; Li, X.; Weaver, A.L.; Lieske, J.C. Kidney stones and the risk for chronic kidney disease. *Clin. J. Am. Soc. Nephrol.* 2009, 4, 804–811. [CrossRef]

5. Ziembta, J.B.; Matlaga, B.R. Epidemiology and economics of nephrolithiasis. *Investig. Clin. Urol.* 2017, 58, 299–306. [CrossRef] [PubMed]

6. West, B.; Luke, A.; Durazo-Arvizu, R.A.; Cao, G.; Shoaham, D.; Kramer, H. Metabolic syndrome and self-reported history of kidney stones: The National Health and Nutrition Examination Survey (NHANES III) 1988–1994. *Am. J. Kidney Dis.* 2008, 51, 741–747. [CrossRef]

7. Jeong, I.G.; Kang, T.; Bang, J.K.; Park, J.; Kim, W.; Hwang, S.S.; Kim, H.K.; Park, H.K. Association between metabolic syndrome and the presence of kidney stones in a screened population. *Am. J. Kidney Dis.* 2011, 58, 383–388. [CrossRef] [PubMed]

8. Chang, I.H.; Lee, Y.T.; Lee, D.M.; Kim, T.H.; Myung, S.C.; Kim, Y.S.; Ahn, S.H. Metabolic syndrome, urine pH, and time-dependent risk of nephrolithiasis in Korean men without hypertension and diabetes. *Urolology* 2011, 78, 753–758. [CrossRef]

9. Chen, C.H.; Lee, J.I.; Jhan, J.H.; Lee, Y.C.; Geng, J.H.; Chen, S.C.; Hung, C.H.; Kuo, C.H. Secondhand smoke increases the risk of developing kidney stone disease. *Sci. Rep.* 2021, 11, 17694. [CrossRef] [PubMed]

10. Liu, W.J. Bidirectional Relationship Between Metabolic Syndrome and Erectile Dysfunction. *Urol. Sci.* 2011, 22, 58–62. [CrossRef]

11. Kikkannongkolchai, W.; Mara, K.C.; Mehta, R.A.; Vaughan, L.E.; Denic, A.; Knoedler, J.J.; Enders, F.T.; Lieske, J.C.; Rule, A.D. Risk of Hypertension among First-Time Symptomatic Kidney Stone Formers. *Clin. Am. Soc. Nephrol.* 2017, 12, 476–482. [CrossRef] [PubMed]

12. Borghi, L.; Meschi, T.; Guerra, A.; Briganti, A.; Schianchi, T.; Allegri, F.; Novarini, A. Essential arterial hypertension and stone disease. *Kidney Int.* 1999, 55, 2397–2406. [CrossRef] [PubMed]

13. Cappuccio, F.P.; Siani, A.; Barba, G.; Mellone, M.C.; Russo, L.; Farinaro, E.; Trevisan, M.; Mancini, M.; Strazzullo, P. A prospective study of hypertension and the incidence of kidney stones in men. *J. Hypertens.* 1999, 17, 1017–1022. [CrossRef]

14. Tisler, A.; Pierratos, A.; Honey, J.D.; Bull, S.B.; Rosivall, L.; Logan, A.G. High urinary excretion of uric acid combined with high lipid-induced oxidative stress in obesity. *Hypertension* 2003, 41, 422–430. [CrossRef] [PubMed]

15. Borghi, L.; Meschi, T.; Guerra, A.; Briganti, A.; Schianchi, T.; Allegri, F.; Novarini, A. Essential arterial hypertension and stone disease. *Kidney Int.* 1999, 55, 2397–2406. [CrossRef] [PubMed]

16. Yoshimura, E.; Sawada, S.S.; Lee, I.M.; Gando, Y.; Kamada, M.; Matsushita, M.; Kawakami, R.; Ando, R.; Okamoto, T.; Tsukamoto, K.; et al. Body Mass Index and Kidney Stones: A Cohort Study of Japanese Men. *J. Epidemiol.* 2016, 26, 131–136. [CrossRef]

17. Wang, Q.; Hu, W.; Lu, Y.; Hu, H.; Zhang, J.; Wang, S. The impact of body mass index on quantitative 24-h urine chemistries in stone forming patients: A systematic review and meta-analysis. *Urolithiasis 2018*, 46, 523–533. [CrossRef]

18. Taylor, E.N.; Stampfer, M.J.; Curhan, G.C. Diabetes mellitus and the risk of nephrolithiasis. *Kidney Int.* 2005, 68, 1230–1235. [CrossRef] [PubMed]

19. Cook, D.G.; Shaper, A.G.; Thelle, D.S.; Whitehead, T.P. Serum uric acid, serum glucose and diabetes: Relationships in a population study. *Postgrad. Med. J.* 1986, 62, 1001–1006. [CrossRef]

20. Torricelli, F.C.; De, S.K.; Gebreseiassie, S.; Li, I.; Sarkissian, C.; Monga, M. Dyslipidemia and kidney stone risk. *J. Urol.* 2014, 191, 667–672. [CrossRef]

21. Kohjimoto, Y.; Sasaki, Y.; Iguchi, M.; Matsumura, N.; Inagaki, T.; Hara, I. Association of metabolic syndrome traits and severity of kidney stones: Results from a nationwide survey on urolithiasis in Japan. *Am. J. Kidney Dis.* 2013, 61, 923–929. [CrossRef]

22. Abate, N.; Chandalia, M.; Cabo-Chan, A.V.; Moser, O.W.; Sakhaee, K. The metabolic syndrome and uric acid nephrolithiasis: Novel features of renal manifestation of insulin resistance. *Kidney Int.* 2004, 65, 386–392. [CrossRef]

23. Stoller, M.L.; Meng, M.V.; Abrahams, H.M.; Kane, J.P. The primary stone event: A new hypothesis involving a vascular etiology. *J. Urol.* 2004, 171, 1920–1924. [CrossRef]

24. Tsai, L.H.; Chang, C.-H.; Chen, S.-J.; Chen, W.-C. Randall’s plaque, the origin of nephrolithiasis: Where do we stand now? *Urol. Sci.* 2019, 30, 200–205.

25. Lopes, H.F.; Martin, K.L.; Nashar, K.; Morrow, J.D.; Goodfriend, T.L.; Egan, B.M. DASH diet lowers blood pressure and lipid-induced oxidative stress in obesity. *Hypertension* 2003, 41, 422–430. [CrossRef] [PubMed]

26. Taylor, E.N.; Fung, T.T.; Curhan, G.C. DASH-style diet associates with reduced risk for kidney stones. *J. Am. Soc. Nephrol.* 2009, 20, 2253–2259. [CrossRef] [PubMed]

27. Wu, C.S.; Lai, M.S.; Gau, S.S.; Wang, S.C.; Tsai, H.J. Concordance between patient self-reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan. *PLoS ONE* 2014, 9, e112257. [CrossRef]
28. Chou, Y.H.; Li, C.C.; Wu, W.J.; Juan, Y.S.; Huang, S.P.; Lee, Y.C.; Liu, C.C.; Li, W.M.; Huang, C.H.; Chang, A.W. Urinary stone analysis of 1000 patients in southern Taiwan. Kaohsiung J. Med. Sci. 2007, 23, 63–66. [CrossRef]

29. Kino, M.; Hayashi, T.; Hino, D.; Nakada, T.; Kitoh, H.; Akakura, K. Patients’ poor performance status is an independent risk factor for urosepsis induced by kidney and ureteral stones. Urolithiasis 2021, 49, 477–484. [CrossRef]